Coya Therapeutics Provides Enrollment Update Of The Investigator-Initiated Phase 1 Study Of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein In Patients With Frontotemporal Dementia; This Open-Label Phase 1 Study Measures Safety, Peripheral And Central Inflammation, Effects On Treg Cell Populations, And FTD Progression; 5 Of The 8 Planned FTD Subjects Have Been Enrolled To Date

This open-label Phase 1 study measures safety, peripheral and central inflammation, effects on Treg cell populations, and FTD progression;

Five of the 8 planned FTD subjects have been enrolled to date;

Results of study will inform Coya's randomized, double-blinded Phase 2 trial of COYA 302 in patients with FTD

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital. Topline results of the study will be leveraged to inform and finalize the planned trial design of a Company-sponsored, randomized, double-blinded Phase 2 trial of COYA 302 in patients with FTD. Coya has been awarded $5 million by the Alzheimer's Drug Discovery Foundation (ADDF) to support the development of COYA 302 in FTD.

The current investigator-initiated study is evaluating the effects of LD IL-2 + CTLA4-Ig on a variety of parameters in patients with FTD, including safety, tolerability, Treg cell populations, peripheral and central inflammation, and disease progression. COYA 302 is a proprietary formulation of this biologic combination therapy, comprised of low dose interleukin-2 (LD IL-2) and cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA4-Ig).